A new Australian blood test for ovarian cancer is showing promise for detecting the disease earlier, before symptoms appear. The Avantect test, developed by BCAL Diagnostics in partnership with US company ClearNote Health, analyses abnormal cell-free DNA and methylation patterns in the bloodstream associated with ovarian tumours.
The article explains that ovarian cancer currently has poor survival outcomes because it is usually diagnosed late, with only around 49% five-year survival overall and just 13% for advanced-stage disease. Early detection dramatically improves outcomes, potentially lifting survival rates to around 90%.
The technology works by identifying tumour-related DNA and messenger RNA signatures in blood. Researchers say it may detect cancer before it can be seen on scans or ultrasounds. Clinical experts quoted in the article describe the test as “really exciting” and potentially a major advancement for high-risk women, particularly those with BRCA mutations or strong family histories.
The test is initially intended for high-risk patients rather than broad population screening because false positives remain a concern. It is available through Sydney Breast Clinic for approximately $495 and is expected to expand to other locations.
